Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Condition:   Testicular Cancer Interventions:   Drug: Veliparib;   Drug: Gemcitabine;   Drug: Carboplatin Sponsor:   National Cancer Institute, Slovakia Recruiting - verified August 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials